CNS Therapies Contribute Rising Share Of Breakthrough Designations
Executive Summary
Breakthrough program could speed first treatments for tardive dyskinesia, primary progressive multiple sclerosis, and Parkinson's psychosis to market, along with new fast-acting approaches to treatment-resistant depression.
You may also be interested in...
Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
Ocrelizumab May Represent Roche’s Rebound In Neuroscience
Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.